Event Details
DIA/FDA's Oligonucleotide-based Therapeutics Conference (Oligo22)
Apr 25 - Apr 27, 2022
Title: Short Interfering RNA JNJ-3989 Combination Therapy
Presenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals
Title: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial
Presenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals
Supporting Materials
DIA FDA 2022 ARO-HIF2 2.2 MB